Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case

Joseph H. Butterfield, Ayalew Tefferi, Gerald F. Kozuh

Research output: Contribution to journalArticle

29 Scopus citations


Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.

Original languageEnglish (US)
Pages (from-to)131-134
Number of pages4
JournalLeukemia Research
Issue number2
StatePublished - Feb 1 2005



  • Interferon-alfa
  • Prostaglandin F
  • Systemic mastocytosis therapy
  • Tryptase
  • c-kit mutation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this